Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.
Overview
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ($48.43).
Details
Boston Scientific Corporation is a global leader in medical technology with a market capitalization of $73 billion and trailing twelve-month (TTM) revenue of $21 billion, employing 59,000 professionals across its operations. The company maintains a diversified business model spanning three strategic segments that collectively address a broad spectrum of clinical needs in interventional medicine. With a TTM net income of $3.7 billion, Boston Scientific demonstrates strong operational profitability and positions itself as a key innovator in the medical device sector, competing on the basis of technological advancement, clinical efficacy, and global market reach.
Source
Originally published at www.fool.com.